Home Cell Cycle CDK CDK4 Inhibitors

CDK4 Inhibitors

  • CDK1
  • CDK2
  • CDK3
  • CDK4
  • CDK5
  • CDK6
  • CDK7
  • CDK9
  • CLK
  • Cdc
Kat.-Nr. Produktname Informationen Selektiv / Pan IC50 / Ki
S2688 R547 R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1. Pan CDK4/CyclinD1, Ki: 1 nM
S7158 LY2835219 LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. Phase 3. Pan CDK4, IC50: 2 nM
S1116 Palbociclib (PD-0332991) HCl Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3. Pan CDK4/CyclinD3, IC50: 9 nM; CDK4/CyclinD1, IC50: 11 nM
S1579 Palbociclib (PD0332991) Isethionate Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3. Pan CDK4/CyclinD3, IC50: 9 nM; CDK4/CyclinD1, IC50: 11 nM
S1230 Flavopiridol (Alvocidib) Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2. Pan CDK4, IC50: 40 nM
S2679 Flavopiridol (Alvocidib) HCl Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2. Pan CDK4, IC50: 40 nM
S1487 PHA-793887 PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. Phase 1. Pan CDK4/CyclinD1, IC50: 62 nM
S8058 P276-00 P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3. Pan CDK4/CyclinD1, IC50: 63 nM
S1524 AT7519 AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 2. Pan CDK4/CyclinD1, IC50: 100 nM
S2751 Milciclib (PHA-848125) Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2. Pan CDK4/CyclinD1, IC50: 160 nM
S7636 SU9516 SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively. Pan CDK4, IC50: 200 nM
S2014 BMS-265246 BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4. Pan CDK4/CyclinD, IC50: 230 nM
S1249 JNJ-7706621 JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1. Pan CDK4/CyclinD1, IC50: 253 nM
S1145 SNS-032 (BMS-387032) SNS-032 has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1. Pan CDK4/CyclinD, IC50: 925 nM
S7461 LDC000067 LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7. Pan CDK4, IC50: 9.242 μM
S7440 LEE011 LEE011 is an orally available, and highly specific CDK4/6 inhibitor. Phase 3. Pan